Frontiers in Oncology, 13:1136221. Frontiers Media S.A. Frontiers in Oncology, 13 Frontiers in Oncology, 13:1136221. Frontiers Media SA Meertens, M, Muntinghe-Wagenaar, M B, Sikkema, B J, Lopez-Yurda, M, Retèl, V P, Paats, M S, ter Heine, R, Schuuring, E, Timens, W, Touw, D J, van Boven, J F M, de Langen, A J, Hashemi, S M S, Hendriks, L E L, Croes, S, van den Heuvel, M M, Dingemans, A-M C, Mathijssen, R H J, Smit, E F, Huitema, A D R, Steeghs, N & van der Wekken, A J 2023, ' Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients : Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC) ', Frontiers in Oncology, vol. 13, 1136221 . https://doi.org/10.3389/fonc.2023.1136221
BMC Cancer, 22(1):941. BioMed Central van der Velden, N C A, van Laarhoven, H W M, Burgers, S A, Hendriks, L E L, de Vos, F Y F L, Dingemans, A-M C, Jansen, J, van Haarst, J-M W, Dits, J, Smets, E M & Henselmans, I 2022, ' Characteristics of patients with advanced cancer preferring not to know prognosis : a multicenter survey study ', BMC Cancer, vol. 22, no. 1, 941, pp. 941 . https://doi.org/10.1186/s12885-022-09911-8 BMC cancer, 22(1):941. BioMed Central BMC Cancer, 22(1):941. BioMed Central Ltd. BMC Cancer, 22(1):941. BioMed Central Ltd